Older HIV-infected adults: complex patients (III)—polypharmacy
- 1 Downloads
Polypharmacy is a well-described problem in the geriatric population. It is a relatively new problem for people living with HIV (PLWH), as this group now has a life expectancy approaching that of the general population. Defining polypharmacy for PLWH is difficult, since the most common traditional definition of at least five medications would encompass a large percentage of PLWH who are on antiretrovirals (ARVs) and medications for other medical comorbidities. Even when excluding ARVs, the prevalence of polypharmacy in PLWH is higher than the general population, and not just in resource-rich countries. Using a more nuanced approach with “appropriate” or “safer” polypharmacy allows for a better framework for discussing how to mitigate the associated risks. Some of the consequences of polypharmacy include adverse effects of medications such as increased risk of geriatric syndromes, drug–drug interactions, decreased adherence, and over- and undertreatment of medical comorbidities. Interventions to combat polypharmacy include decreasing pill burden—specifically with fixed-dose combination tablets—and medication reconciliation/de-prescription using established criteria. The goal of these interventions is to decrease drug interactions and improve quality of life and outcomes. Some special populations of interest within the community of PLWH include those with chronic pain, substance abuse, or requiring end of life care. A final look into the future of antiretroviral therapy shows the promise of possible two-drug regimens, which can help reduce the above risks of polypharmacy.
KeywordsPolypharmacy Geriatric HIV Medication appropriateness Adverse drug reactions Drug interactions
Dr. Johnston receives support from NIH TL1 TR000459 and NIAID T32AI007613. Dr. Siegler receives support from Gilead Sciences, Inc. for an investigator-initiated study IN-US-311-4182.
Compliance with ethical standards
Conflict of interest
Dr. Siegler receives support from Gilead Sciences for an investigator-initiated study. Dr. Faragon is on the speakers’ bureaus of AbbVie, Gilead Sciences, Merck, and Janssen Pharmaceutical. Drs. Freedman, Johnston, and Del Carmen report no conflicts of interest.
The preparation of this review did not involve human or animal participants.
No informed consent was required.
- 1.UNAIDS UNAIDS—AIDSinfo. http://aidsinfo.unaids.org/. Accessed 8 Oct 2018
- 2.CDC HIV among people aged 50 and older. https://www.cdc.gov/hiv/group/age/olderamericans/index.html. Accessed 29 Sept 2018
- 4.Duerden M, Avery T, Payne R (2013) Polypharmacy and medicines optimisation. Making it safe and sound. The King’s Fund, London. https://www.kingsfund.org.uk/sites/default/files/field/field_publication_file/polypharmacy-and-medicinesoptimisation-kingsfund-nov13.pdf. Accessed 12 Sept 2018Google Scholar
- 15.Guaraldi G, Malagoli A, Calcagno A et al (2018) The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65–74 years and more than 75 years. BMC Geriatr 18:99. https://doi.org/10.1186/s12877-018-0789-0 CrossRefGoogle Scholar
- 19.Liverpool HIV drug interactions. https://www.hiv-druginteractions.org/checker. Accessed 29 Sept 2018
- 20.U.S. Department of Health and Human Services (DHHS) Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0. Accessed 8 Oct 2018
- 22.Gilead Sciences (2018) Bictegravir/tenofovir alafenamide/emtricitabine [Package Insert]. https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf. Accessed 30 Sept 2018
- 24.Mills A, Arribas JR, Andrade-Villanueva J et al (2016) Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis 16:43–52. https://doi.org/10.1016/S1473-3099(15)00348-5 CrossRefGoogle Scholar
- 37.Huang ES, Karter AJ, Danielson KK et al (2010) The association between the number of prescription medications and incident falls in a multi-ethnic population of adult type-2 diabetes patients: the diabetes and aging study. J Gen Intern Med 25:141–146. https://doi.org/10.1007/s11606-009-1179-2 CrossRefGoogle Scholar
- 44.Freiberg MS, Leaf DA, Goulet JL et al (2009) The association between the receipt of lipid lowering therapy and HIV status among veterans who met NCEP/ATP III criteria for the receipt of lipid lowering medication. J Gen Intern Med 24:334–340. https://doi.org/10.1007/s11606-008-0891-7 CrossRefGoogle Scholar
- 46.Portsmouth SD, Osorio J, McCormick K et al (2005) Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med 6:185–190. https://doi.org/10.1111/j.1468-1293.2005.00287.x CrossRefGoogle Scholar
- 47.Airoldi M, Zaccarelli M, Bisi L et al (2010) One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence 4:115–125Google Scholar
- 50.Blanco JR, Caro AM, Pérez-Cachafeiro S et al (2010) HIV infection and aging. AIDS Rev 12:218–230Google Scholar
- 57.Janssen prezcobix (darunavir and cobicistat) [Package Insert]. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/PREZCOBIXpi.pdf. Accessed 30 Sept 2018
- 65.CDC HIV/AIDS. https://www.cdc.gov/hiv/default.html. Accessed 29 Sept 2018
- 67.Gruta C, Goldschmidt R (2017) HIV/AIDS: implications for older adult patients. https://aging.arizona.edu/sites/aging/files/fact-sheet-pdfs/hiv_1.pdf. Accessed 29 Sept 2018
- 80.Friedland GH, Williams A (1999) Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 13(Suppl 1):S61–S72Google Scholar
- 81.Llibre JM, Hung C-C, Brinson C et al (2018) Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet 391:839–849. https://doi.org/10.1016/S0140-6736(17)33095-7 CrossRefGoogle Scholar
- 82.Aboud M, Orkin C, Podzamczer D, Boger J (2018) Durable suppression 2 years after switch to DTG +RPV 2-drug regimen: SWORD-1 and SWORD-2 studies, 22nd International AIDS Conference, Amsterdam, Netherlands, July 23–27, 2018Google Scholar
- 83.ViiV Healthcare (2016) An efficacy, safety, and tolerability study comparing dolutegravir plus lamivudine with dolutegravir plus tenofovir/emtricitabine in treatment naïve HIV infected subjects (Gemini 1). In: NCT02831673. https://clinicaltrials.gov/ct2/show/NCT02831673. Accessed 27 Sept 2018
- 84.ViiV Healthcare (2016) An efficacy, safety, and tolerability study comparing dolutegravir (DTG) plus lamivudine (3TC) with dolutegravir plus tenofovir/emtricitabine in treatment naïve HIV infected subjects (Gemini 2). In: NCT02831764. https://clinicaltrials.gov/ct2/show/NCT02831764. Accessed 28 Sept 2018